Minovés-Kotzki
Welcome,         Profile    Billing    Logout  
 21 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pépin, Jean-Louis JP
keePaOSA, NCT04875897: Efficacy and Safety of keepMED Positive Airway Pressure Device in Patients With Obstructive Sleep Apnea

Not yet recruiting
N/A
65
NA
keepMED PAP device
keepMED Ltd., CRI-The Clinical Research Institute GmbH
Obstructive Sleep Apnea
01/22
02/22
NCT05698602: Safety and Performance of NivolisMonitor and NivolisAnton for Monitoring Patients on Ventilatory Assistance at Home

Active, not recruiting
N/A
10
Europe
NivolisMonitor, NivolisAnton
VIVARDIS
Respiratory Insufficiency, Respiratory Failure, Home Monitoring
07/25
12/25
WIVOP-Scales, NCT05823025: Withings Study to Analyze the Accuracy of Pulse Wave Velocity Measurement With Bathroom Scales

Not yet recruiting
N/A
176
Europe
PWV measurement
Withings
Vascular Stiffness
05/24
11/24
SCOOP-RNPC, NCT05857319: Study Consortium for Evaluation of RNPC Program in Obese and Overweight Patients

Not yet recruiting
N/A
10000
NA
Nutritional Psycho-Behavioral Reeducation Program, RNPC Program
Groupe Éthique et Santé, University Grenoble Alps, Novo Nordisk A/S, Lyon Est University
Overweight and Obesity, Cardiovascular Diseases, Metabolic Disease, Diabete Type 2, Sleep Apnea, Obstructive, NAFLD, NASH
07/30
07/30
DECAENS, Thomas
ROWAN, NCT05063565: TheraSphere With Durvalumab and Tremelimumab for HCC

Recruiting
2
100
Europe, US
TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy
Boston Scientific Corporation, Biocompatibles UK Ltd
Hepatocellular Carcinoma
06/27
06/27
BLANC, Jean-Frédéric
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Active, not recruiting
3
556
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
09/24
10/24
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
LATOURNERIE, Marianne
ProPILARifax, NCT03069131: Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites

Completed
3
160
Europe
Rifaximin, Placebo
Centre Hospitalier Universitaire de Besancon, Alfasigma S.p.A., LC2 PHARMA
Cirrhosis, Ascites, Peritonitis
06/22
03/23
REGNAULT, Hélène
SIRtain, NCT05967143: Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors ( Registry)

Recruiting
N/A
845
Europe
SIRT
Sirtex Medical
Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
06/28
06/29
BOUATTOUR, Mohamed
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
NCT05733598: RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Not yet recruiting
2
60
Europe, US
RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
04/27
07/27
SIRtain, NCT05967143: Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors ( Registry)

Recruiting
N/A
845
Europe
SIRT
Sirtex Medical
Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
06/28
06/29
SOBESKY, Rodolphe
No trials found

Download Options